Biology subjects

McGuffin, P.

Publications and source records attributed to McGuffin, P..

3 recordsLinked to original sources

bioRxiv2018

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies

Cytochrome (CYP) P450 enzymes have a primary role in antidepressant metabolism and variants in these polymorphic genes are targets for pharmacogenetic investigation. This is the first meta-analysis to investigate how CYP2C19 polymorphisms predict citalopram/escitalopram efficacy and side effects.\n\nCYP2C19 phenotypes comprise poor metabolizers (PM), intermediate and intermediate+ metabolizers (IM; IM+), extensive and extensive+ metabolizers (EM [wild type]; EM+) and ultra-rapid metabolizers (UM) defined by the two most common CYP2C19 functional polymorphisms (rs4244285 and rs12248560) in Caucasians. These polymorphisms were genotyped or imputed from genome-wide data in four samples treated with citalopram or escitalopram (GENDEP, STAR*D, GenPod, PGRN-AMPS). Treatment efficacy was percentage symptom improvement and remission. Side effect data were available at weeks 2-4, 6 and 9 in three of the investigated samples. A fixed-effects meta-analysis was performed using EM as the reference group.\n\nAnalysis of 2558 patients for efficacy and 2037 patients for side effects showed that PMs had higher symptom improvement (SMD=0.43, CI=0.19-0.66) and higher remission rates (OR=1.55, CI=1.23-1.96) compared to EMs. At weeks 2-4, PMs showed higher risk of gastro-intestinal (OR=1.26, CI=1.08-1.47), neurological (OR=1.28, CI=1.07-1.53) and sexual side effects (OR=1.52, CI=1.23-1.87; week 6 values similar). No difference was seen at week 9 or in total side effect burden. PMs did not have higher risk of dropout at week 4 compared to EMs. Antidepressant dose was not different among CYP2C19 groups.\n\nCYP2C19 polymorphisms may provide helpful information for guiding citalopram/escitalopram treatment, despite PMs are relatively rare among Caucasians (~2%).

genetics↗

bioRxiv2017

New insights on the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation

Genome-wide association studies have generally failed to identify polymorphisms associated with antidepressant response. Possible reasons include limited coverage of genetic variants that this study tried to address by exome genotyping and dense imputation.\n\nA meta-analysis of Genome-Based Therapeutic Drugs for Depression (GENDEP) and Sequenced Treatment Alternatives to Relieve Depression (STAR*D) studies was performed at SNP, gene and pathway level. Coverage of genetic variants was increased compared to previous studies by adding exome genotypes to previously available genome-wide data and using the Haplotype Reference Consortium panel for imputation. Standard quality control was applied. Phenotypes were symptom improvement and remission after 12 weeks of antidepressant treatment. NEWMEDS consortium samples and Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) served for replication.\n\n7,062,950 SNPs were analysed in GENDEP (n=738) and STAR*D (n=1409). rs116692768 (p=1.80e-08, ITGA9 (integrin alpha 9)) and rs76191705 (p=2.59e-08, NRXN3 (neurexin 3)) were significantly associated with symptom improvement during citalopram/escitalopram treatment. At gene level, no consistent effect was found. At pathway level, the Gene Ontology terms GO:0005694 (chromosome) and GO:0044427 (chromosomal part) were associated with improvement (corrected p=0.007 and 0.045, respectively). The association between rs116692768 and symptom improvement was replicated in PGRN-AMPS (p=0.047), while rs76191705 was not. The two SNPs did not replicate in NEWMEDS.\n\nITGA9 codes for a membrane receptor for neurotrophins and NRXN3 is a transmembrane neuronal adhesion receptor involved in synaptic differentiation. Despite their meaningful biological rationale for being involved in antidepressant effect, no convincing replication was achieved. Further studies may help in clarifying their role.

genomics↗

bioRxiv2017

Whole genome linkage analysis in a large Brazilian multigenerational family reveals distinct linkage signals for Bipolar Disorder and Depression.

Both common and rare genetic variation play a role in the causes for mood disorders. Very large families pose unique opportunities and analytical challenges but may provide a way to identify regions and mutations associated with mood disorders. We identified a family with a high prevalence (~30%) of mood disorders in a rural village in Brazil, featuring decreasing age of onset over generations. The pattern of inheritance was complex with 32 Bipolar type I cases, 11 Bipolar type II and 59 recurrent and/or severe Depression cases in addition to other phenotypes. We enrolled 333 participants with DNA samples from a broader pedigree of 960 subjects for genotyping using the Affymetrix 10K array. Non-parametric linkage was carried out via MERLIN and parametric with both MERLIN and MCLINKAGE. We exome sequenced a subset of the family (n=27) in order to identify rare variation within the linkage regions shared by affected family members. We identified four genome wide significant and four suggestive linkage regions on chromosomes 1, 2, 3, 11 and 12 for different phenotype definitions. However, no region received strong joint support in both the parametric and non-parametric analyses. Exome sequencing revealed potential deleterious variants in 11p15.4 for MDD and 1q21.1-1q21.3 and 12p23.1-p22.3, implicated in cell signaling, adhesion, translation and neurogenesis processes. Overall, our results suggest promising, but not definitive or confirmed evidence, that rare genetic variation contributes to the high prevalence of mood disorders in this multi-generational family. We note that a substantial role for common genetic variation is likely given the strength of the linkage signals observed.\n\nThe World Health Organisation reports depression and bipolar disorder as the second and seventh most important causes of years lost due to disability worldwide[1]. The heritability of bipolar disorder is between 60-90% with a lower but still substantial heritability for major depression (40-45%) [2]; [3]. First-degree relatives of bipolar disorder probands have a 5-10 fold increase in risk of developing the illness compared to relatives of controls but also show a three fold increase in unipolar depression, indicating that bipolar disorder does not \"breed true\" [4]. Large collaborative genome-wide association studies (GWAS) have uncovered several common genetic variants of small effect [5]. Genomewide estimates of heritability suggest that up to 60% of the genetic risk is contributed by common variants [6]. Overall, the current picture for bipolar disorder (and almost all complex traits) is a genetic architecture formed of both common and rare variants.\n\nLinkage studies have been pursued on the basis that there may be variants of greater effect shared between and within affected families. However these studies have usually focused on collections of comparatively small families or sib pairs and few consistent findings have emerged [7]. Large multigenerational families (e. g. of >30 affected individuals) theoretically offer a powerful means for mapping complex disease loci that are individually rare but common in a single family. These loci may be more highly penetrant and of larger effect than loci found with GWAS [8]. Here we report the results of the Brazilian Bipolar Family (BBF) study on a five-generation family of 639 members of which 333 were enrolled in the current analyses. Our objectives were to perform a linkage analysis with genome coverage and try to identify new genes/mutations related to bipolar and other mood disorders in the family. Here we report our findings and preliminary results of sequencing of linkage regions.

genetics↗